Drug Trial Radar · NCT07536308
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Actual
Start
May 26, 2026
Primary completion
Apr 29, 2027
Study completion Nov 1, 2027
Sponsor
- Sponsor type
- NIH
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10\^10 viral particles (VP) and 5×10\^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults.
Conditions
- COVID-19
Interventions
OCU500Biological
OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of abnormal clinical safety laboratory adverse events (AE).Time frame: Through Day 8
- Occurrence of adverse events of special interest (AESI).Time frame: Through 6 months post study product administration
- Occurrence of medically attended adverse events (MAAEs).Time frame: Through 6 months post study product administration
- Occurrence of new-onset chronic medical conditions (NOCMCs).Time frame: Through 6 months post study product administration
- Occurrence of serious adverse events (SAEs).Time frame: Through 6 months post study product administration
- Occurrence of solicited local adverse events (AEs).Time frame: Through Day 8
- Occurrence of solicited systemic adverse events (AEs).Time frame: Through Day 8
- Occurrence of unsolicited adverse events (AEs).Time frame: Through Day 29
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The Hope Clinic of Emory University
Decatur, Georgia
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Saint Louis University Center for Vaccine Development
St Louis, Missouri
University of Texas Medical Branch
Galveston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.